

Celsion Corporation Investor Relations Department 997 Lenox Drive Suite 100 Lawrenceville, NJ 08648 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: CLSN	
Last Trade:	0.24
Trade Time:	3:59 PM ET May 25, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.19 - 1.60
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the sideeffects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heatsensitive liposomal nanoparticle licensed from Duke Universit... (more)

Stock Performance



Press Releases [View all]

May 12, 2017

<u>Celsion Corporation Reports First Quarter</u> <u>2017 Financial Results and Provides</u> Business Update

May 5, 2017

Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017

May 4, 2017

Celsion Updates Clinical Data from the OVATION Study in Newly
Diagnosed Â Advanced Ovarian Cancer
Patients

Apr 20, 2017

Celsion Announces Presentation of
OVATION Study Findings at the Upcoming
ASCO 2017 Annual Meeting

Apr 13, 2017

Celsion Corporation Reports Preclinical
Results of ThermoDox® for the Treatment of
Bladder Cancer Published in the International
Journal of Hyperthermia

Financials [View all]

First Quarter Financial Results

Mar 24, 2017

Annual Report (10-K)

Apr 4, 2017

Proxy Statement (DEF 14A)

May 12, 2017

Quarterly Report (10-Q)

Nov 10, 2016

Quarterly Report (10-Q)

Aug 15, 2016

Quarterly Report (10-Q)